Global Post Traumatic Stress Disorder Therapeutics Market - 2024-2031

Global Post Traumatic Stress Disorder Therapeutics Market - 2024-2031

Global Post Traumatic Stress Disorder Therapeutics Market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing at a CAGR of XX% during the forecast period 2024-2031

Posttraumatic stress disorder (PTSD) is a psychological disorder that affects people who have encountered or seen traumatic events, occurrences, or conditions. It may be both emotionally and physically destructive, impacting one's mental, physical, social, and spiritual health. Natural catastrophes, accidents, terrorism, war, rape, historical trauma, intimate relationship abuse, and bullying are among examples.

Market Dynamics: Drivers & Restraints

Drivers

Rise in the prevalence of post-traumatic stress disorders

Post-traumatic stress disorder (PTSD) is a global health concern, arising from exposure to traumatic events like military combat, natural disasters, accidents, or personal assaults. The increasing prevalence of PTSD, especially among military personnel, first responders, and victims of violence or disasters, is boosting demand for effective treatments and improved diagnosis. For instance, It affects 3.5% of U.S. adults annually, with an estimated one in 11 diagnosed in their lifetime. Women are twice as likely as men to have PTSD.

Restraints

Side effects associated with the drugs

The global post-traumatic stress disorder treatment market faces a significant challenge due to the lack of awareness and understanding of side effects associated with drugs like Sertraline and Paroxetine. Sertraline has various side effects like syncope, lightheadedness, diarrhea, nausea, and more, while Paroxetine has side effects like mood changes, anxiety, serotonin syndrome, eye problems, allergic reactions, bruising, seizures, manic episodes, changes in appetite or weight, low sodium levels, and bone fractures.

Segment Analysis

The global post-traumatic stress disorder therapeutics market is segmented based on drug type, age group, route of administration, end-user, and region.

The anti-depressants from the drug type segment accounted for approximately 45.3 % of the post-traumatic stress disorder therapeutics market share

The anti-depressants from the drug type segment accounted for approximately 45.3 %. SSRIs are commonly used antidepressants to treat depression and anxiety associated with PTSD. They increase serotonin levels in the brain, which regulates mood, appetite, and sleep, improving nerve cell communication, leading to improved mood and decreased anxiety. The industry is utilizing competitive strategies like mergers, acquisitions, distribution channel enhancement, product development, and research partnerships to develop effective antidepressant drugs and maintain competitiveness which overall help the segment growth during the forecast period.

Geographical Analysis

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like the novel product launches, FDA approvals, rising prevalence of the PTSD and increasing patient awareness about mental health and other factors help the region to grow during the forecast period.

For instance, in January 2024, Otsuka Pharmaceutical, Co. Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced the U.S. Food and Drug Administration (FDA) has determined that the supplemental New Drug Application (sNDA) for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD) is sufficiently complete to permit a substantive review. The FDA has assigned the application for a Prescription Drug User Fee Act (PDUFA) target action date of February 8, 2025.

Market Segmentation

By Drug Type
• Antidepressants
Selective Serotonin Reuptake Inhibitors
Serotonin—Norepinephrine Reuptake Inhibitor
MAO Inhibitors
Tricyclic Antidepressants
• Anti-anxiety Drugs
Beta-blockers
Benzodiazepines
• Antipsychotics
• Others

By Age Group
• Adults
• Children

By Route of Administration
• Oral
• Parenteral
• Transdermal

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Pfizer Inc, Eli Lily and Company, GlaxoSmithKline Plc, H. Lundbeck, Otsuka Pharmaceutical Co., Ltd, Novartis AG, AstraZeneca Plc, Azevan Pharmaceuticals, Inc, Bionomics Ltd, Tonix, Pharmaceuticals Holding Corp, Apotex, Incamong others.

Key Developments

 In April 2024, The University of the Sunshine Coast established the National PTSD Research Centre, a $18.5 million national hub, to address the mental health issue of PTSD, which affects nearly half of Australians directly or indirectly.

Why Purchase the Report?
• To visualize the global post-traumatic stress disorder therapeutics market segmentation based on drug type, age group, route of administration, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the post-traumatic stress disorder therapeutics market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global post-traumatic stress disorder therapeutics market report would provide approximately 64 tables, 61 figures, and 186 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies